Tuesday 25 November 2014
Withdrawal of the marketing authorisation application for balugrastim
On 4 November 2014, Teva Pharma B.V. officially notified the European
Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP)
that it wishes to withdraw its application for a marketing
authorisation for balugrastim (Egranli), for reduction in the duration
of neutropaenia and the occurrence of febrile neutropaenia in adult
cancer patients. Read more here.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment